{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T16:03:17Z","timestamp":1774454597008,"version":"3.50.1"},"reference-count":102,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgonc.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.soc.2018.02.006","type":"journal-article","created":{"date-parts":[[2018,6,20]],"date-time":"2018-06-20T23:22:45Z","timestamp":1529536965000},"page":"519-537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Evolving Treatment Strategies and Outcomes in Advanced Gastric Cancer with Peritoneal Metastasis"],"prefix":"10.1016","volume":"27","author":[{"given":"Fadi S.","family":"Dahdaleh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiran K.","family":"Turaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.soc.2018.02.006_bib1","first-page":"69","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.soc.2018.02.006_bib2","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/978-1-60327-492-0_23","article-title":"Epidemiology of stomach cancer","volume":"472","author":"Brenner","year":"2009","journal-title":"Methods Mol Biol"},{"issue":"5","key":"10.1016\/j.soc.2018.02.006_bib3","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1097\/01.sla.0000143245.28656.15","article-title":"Patterns of initial recurrence in completely resected gastric adenocarcinoma","volume":"240","author":"D'Angelica","year":"2004","journal-title":"Ann Surg"},{"issue":"13","key":"10.1016\/j.soc.2018.02.006_bib4","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.1245\/s10434-016-5409-7","article-title":"Yield of staging laparoscopy and lavage cytology for radiologically occult peritoneal carcinomatosis of gastric cancer","volume":"23","author":"Ikoma","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.soc.2018.02.006_bib5","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/ijc.28373","article-title":"Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors","volume":"134","author":"Thomassen","year":"2014","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.soc.2018.02.006_bib6","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O","article-title":"Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study","volume":"88","author":"Sadeghi","year":"2000","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.soc.2018.02.006_bib7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/01.sla.0000197382.43208.a5","article-title":"Clinical outcomes with laparoscopic stage M1, unresected gastric adenocarcinoma","volume":"243","author":"Sarela","year":"2006","journal-title":"Ann Surg"},{"issue":"10","key":"10.1016\/j.soc.2018.02.006_bib8","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1245\/s10434-010-1090-4","article-title":"Prognostic significance of free peritoneal tumor cells in the peritoneal cavity before and after neoadjuvant chemotherapy in patients with gastric carcinoma undergoing potentially curative resection","volume":"17","author":"Lorenzen","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.soc.2018.02.006_bib9","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1245\/s10434-008-0055-3","article-title":"Does neoadjuvant treatment for gastric cancer patients with positive peritoneal cytology at staging laparoscopy improve survival?","volume":"15","author":"Badgwell","year":"2008","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.soc.2018.02.006_bib10","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1245\/s10434-010-1183-0","article-title":"Positive peritoneal cytology in patients with gastric cancer: natural history and outcome of 291 patients","volume":"17","author":"Mezhir","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.soc.2018.02.006_bib11","doi-asserted-by":"crossref","first-page":"e37284","DOI":"10.1371\/journal.pone.0037284","article-title":"Long-term results and prognostic factors of gastric cancer patients with microscopic peritoneal carcinomatosis","volume":"7","author":"Liu","year":"2012","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.soc.2018.02.006_bib12","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.6004\/jnccn.2016.0138","article-title":"Advances in systemic therapy for metastatic or advanced gastric cancer","volume":"14","author":"Shitara","year":"2016","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"5","key":"10.1016\/j.soc.2018.02.006_bib13","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1200\/JCO.2015.62.6598","article-title":"Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013\/LOGiC\u2013a randomized phase III trial","volume":"34","author":"Hecht","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.soc.2018.02.006_bib14","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","article-title":"Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial","volume":"17","author":"Muro","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.soc.2018.02.006_bib15","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","article-title":"Capecitabine and oxaliplatin for advanced esophagogastric cancer","volume":"358","author":"Cunningham","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.soc.2018.02.006_bib16","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/(SICI)1097-0142(19970301)79:5<884::AID-CNCR3>3.0.CO;2-C","article-title":"Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery","volume":"79","author":"Fujimoto","year":"1997","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.soc.2018.02.006_bib17","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/bjs.4695","article-title":"Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion","volume":"92","author":"Yonemura","year":"2005","journal-title":"Br J Surg"},{"issue":"4","key":"10.1016\/j.soc.2018.02.006_bib18","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1002\/1097-0142(197910)44:4<1476::AID-CNCR2820440442>3.0.CO;2-R","article-title":"Intraperitoneal free cancer cells and their viability in gastric cancer","volume":"44","author":"Iitsuka","year":"1979","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.soc.2018.02.006_bib19","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/BF00402474","article-title":"Prognostic significance of intraperitoneal free cancer cells in gastric cancer patients","volume":"108","author":"Koga","year":"1984","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"2","key":"10.1016\/j.soc.2018.02.006_bib20","first-page":"678","article-title":"Mechanisms of peritoneal metastasis after operation for non-serosa-invasive gastric carcinoma: an ultrarapid detection system for intraperitoneal free cancer cells and a prophylactic strategy for peritoneal metastasis","volume":"9","author":"Marutsuka","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.soc.2018.02.006_bib21","doi-asserted-by":"crossref","first-page":"174","DOI":"10.4149\/neo_2013_023","article-title":"D2 lymphadenectomy can disseminate tumor cells into peritoneal cavity in patients with advanced gastric cancer","volume":"60","author":"Yu","year":"2013","journal-title":"Neoplasma"},{"issue":"4","key":"10.1016\/j.soc.2018.02.006_bib22","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/ssu.10042","article-title":"Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancer","volume":"21","author":"Sugarbaker","year":"2003","journal-title":"Semin Surg Oncol"},{"issue":"4 Suppl 6","key":"10.1016\/j.soc.2018.02.006_bib23","first-page":"83","article-title":"Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer","volume":"16","author":"Sugarbaker","year":"1989","journal-title":"Semin Oncol"},{"key":"10.1016\/j.soc.2018.02.006_bib24","unstructured":"NCCN Clinical Practice Guidelines in Oncology. 2016. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/gastric_blocks.pdf. Accessed April 28, 2017."},{"issue":"3","key":"10.1016\/j.soc.2018.02.006_bib25","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4251\/wjgo.v9.i3.121","article-title":"Gastric peritoneal carcinomatosis - a retrospective review","volume":"9","author":"Tan","year":"2017","journal-title":"World J Gastrointest Oncol"},{"issue":"14","key":"10.1016\/j.soc.2018.02.006_bib26","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2005.05.2308","article-title":"Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world","volume":"24","author":"Kamangar","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.soc.2018.02.006_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004064.pub3","article-title":"Chemotherapy for advanced gastric cancer","author":"Wagner","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.soc.2018.02.006_bib28","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4251\/wjgo.v2.i2.85","article-title":"Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer","volume":"2","author":"Yonemura","year":"2010","journal-title":"World J Gastrointest Oncol"},{"issue":"18","key":"10.1016\/j.soc.2018.02.006_bib29","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1200\/JCO.2005.05.0245","article-title":"Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data","volume":"24","author":"Wagner","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.soc.2018.02.006_bib30","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/jjco\/hyt114","article-title":"Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106)","volume":"43","author":"Shirao","year":"2013","journal-title":"Jpn J Clin Oncol"},{"issue":"9","key":"10.1016\/j.soc.2018.02.006_bib31","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1093\/annonc\/mdn169","article-title":"HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target","volume":"19","author":"Gravalos","year":"2008","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.soc.2018.02.006_bib32","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2559.2008.03028.x","article-title":"Assessment of a HER2 scoring system for\u00a0gastric cancer: results from a validation study","volume":"52","author":"Hofmann","year":"2008","journal-title":"Histopathology"},{"issue":"2","key":"10.1016\/j.soc.2018.02.006_bib33","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/annonc\/mdi064","article-title":"Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab","volume":"16","author":"Tanner","year":"2005","journal-title":"Ann Oncol"},{"issue":"9742","key":"10.1016\/j.soc.2018.02.006_bib34","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.soc.2018.02.006_bib35","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/jso.22017","article-title":"Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity","volume":"104","author":"Gill","year":"2011","journal-title":"J\u00a0Surg Oncol"},{"issue":"6","key":"10.1016\/j.soc.2018.02.006_bib36","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S1470-2045(13)70102-5","article-title":"Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial","volume":"14","author":"Lordick","year":"2013","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.soc.2018.02.006_bib37","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3748\/wjg.v8.i4.591","article-title":"Relationship between the expression of iNOS,VEGF,tumor angiogenesis and gastric cancer","volume":"8","author":"Song","year":"2002","journal-title":"World J Gastroenterol"},{"issue":"30","key":"10.1016\/j.soc.2018.02.006_bib38","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1200\/JCO.2011.36.2236","article-title":"Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study","volume":"29","author":"Ohtsu","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.soc.2018.02.006_bib39","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.4049\/jimmunol.176.5.3000","article-title":"Expression of B7-H1 on gastric epithelial cells: its potential role in regulating T\u00a0cells during Helicobacter pylori infection","volume":"176","author":"Das","year":"2006","journal-title":"J\u00a0Immunol"},{"issue":"4","key":"10.1016\/j.soc.2018.02.006_bib40","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"6349","key":"10.1016\/j.soc.2018.02.006_bib41","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.soc.2018.02.006_bib42","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10147-014-0701-7","article-title":"Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance","volume":"20","author":"Geng","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.soc.2018.02.006_bib43","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1200\/EDBK_175231","article-title":"Immunotherapy for esophageal and gastric cancer","volume":"37","author":"Kelly","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"suppl 4S","key":"10.1016\/j.soc.2018.02.006_bib44","article-title":"Nivolumab (ONO-4538\/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): a double-blinded, randomized, phase III trial","volume":"35","author":"Yoon-Koo Kang","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.soc.2018.02.006_bib45","first-page":"143","article-title":"Cytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review-past, present and future","volume":"7","author":"Dehal","year":"2016","journal-title":"J\u00a0Gastrointest Oncol"},{"issue":"5","key":"10.1016\/j.soc.2018.02.006_bib46","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1245\/s10434-011-2158-5","article-title":"Risk factors for peritoneal recurrence in stage II\/III gastric cancer patients who received S-1 adjuvant chemotherapy after D2 gastrectomy","volume":"19","author":"Aoyama","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.soc.2018.02.006_bib47","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/1097-0142(19880115)61:2<232::AID-CNCR2820610205>3.0.CO;2-U","article-title":"Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C","volume":"61","author":"Koga","year":"1988","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.soc.2018.02.006_bib48","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1002\/1097-0142(19940415)73:8<2048::AID-CNCR2820730806>3.0.CO;2-Q","article-title":"Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study","volume":"73","author":"Hamazoe","year":"1994","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.soc.2018.02.006_bib49","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00280-013-2332-5","article-title":"Enhanced efficacy of postoperative adjuvant chemotherapy in advanced gastric cancer: results from a phase 3 randomized trial (AMC0101)","volume":"73","author":"Kang","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.soc.2018.02.006_bib50","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/SLA.0b013e3181b0c80e","article-title":"Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma","volume":"250","author":"Kuramoto","year":"2009","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.soc.2018.02.006_bib51","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/jso.24476","article-title":"Adjuvant intraperitoneal chemotherapy for the treatment of gastric cancer at risk for peritoneal carcinomatosis: a systematic review","volume":"115","author":"Feingold","year":"2017","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.soc.2018.02.006_bib52","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/1471-2407-14-183","article-title":"GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study","volume":"14","author":"Glehen","year":"2014","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.soc.2018.02.006_bib53","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/jjco\/hyw153","article-title":"Extensive peritoneal lavage after curative gastrectomy for gastric cancer (EXPEL): study protocol of an international multicentre randomised controlled trial","volume":"47","author":"Kim","year":"2017","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.soc.2018.02.006_bib54","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2016.34.4_suppl.tps186","article-title":"A\u00a0phase II study of laparoscopic hyperthermic intraperitoneal chemoperfusion (HIPEC) for gastric carcinomatosis or positive cytology","author":"Badgwell","year":"2016","journal-title":"American Society of Clinical Oncology"},{"issue":"11","key":"10.1016\/j.soc.2018.02.006_bib55","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1245\/s10434-017-6047-4","article-title":"Phase II trial of laparoscopic hyperthermic intraperitoneal chemoperfusion for peritoneal carcinomatosis or positive peritoneal cytology in patients with gastric adenocarcinoma","volume":"24","author":"Badgwell","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.soc.2018.02.006_bib56","first-page":"291","article-title":"Evaluation of palliative resection in advanced carcinoma of the stomach","volume":"77","author":"Stern","year":"1975","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.soc.2018.02.006_bib57","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00000658-198807000-00005","article-title":"Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding","volume":"208","author":"Fujimoto","year":"1988","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.soc.2018.02.006_bib58","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0039-6060(96)80145-0","article-title":"Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination","volume":"119","author":"Yonemura","year":"1996","journal-title":"Surgery"},{"issue":"2B","key":"10.1016\/j.soc.2018.02.006_bib59","first-page":"1375","article-title":"Intraperitoneal chemo-hyperthermia with mitomycin C for gastric cancer patients with peritoneal carcinomatosis","volume":"19","author":"Sayag-Beaujard","year":"1999","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.soc.2018.02.006_bib60","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1001\/archsurg.139.1.20","article-title":"Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer","volume":"139","author":"Glehen","year":"2004","journal-title":"Arch Surg"},{"issue":"9","key":"10.1016\/j.soc.2018.02.006_bib61","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1245\/s10434-010-1039-7","article-title":"Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy","volume":"17","author":"Glehen","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.soc.2018.02.006_bib62","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1245\/s10434-011-1631-5","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial","volume":"18","author":"Yang","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.soc.2018.02.006_bib63","unstructured":"Charite University B, Germany, Aid GC. Cytoreductive Surgery (CRS) with\/without HIPEC in gastric cancer with peritoneal carcinomatosis. 2014. Available at: https:\/\/clinicaltrials.gov\/show\/NCT02158988. Accessed June 27, 2017."},{"issue":"3","key":"10.1016\/j.soc.2018.02.006_bib64","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S1055-3207(03)00035-8","article-title":"Effective therapy for peritoneal dissemination in gastric cancer","volume":"12","author":"Yonemura","year":"2003","journal-title":"Surg Oncol Clin N Am"},{"issue":"4","key":"10.1016\/j.soc.2018.02.006_bib65","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/jso.21324","article-title":"Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: selection for cytoreductive surgery","volume":"100","author":"Yonemura","year":"2009","journal-title":"J\u00a0Surg Oncol"},{"issue":"4","key":"10.1016\/j.soc.2018.02.006_bib66","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1245\/s10434-013-3443-2","article-title":"Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan","volume":"21","author":"Canbay","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.soc.2018.02.006_bib67","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s10120-016-0684-3","article-title":"Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings","volume":"20","author":"Ishigami","year":"2017","journal-title":"Gastric Cancer"},{"issue":"2","key":"10.1016\/j.soc.2018.02.006_bib68","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1245\/s10434-016-5487-6","article-title":"Effects of neoadjuvant laparoscopic hyperthermic intraperitoneal chemotherapy and neoadjuvant intraperitoneal\/systemic chemotherapy on peritoneal metastases from gastric cancer","volume":"24","author":"Yonemura","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.soc.2018.02.006_bib69","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1200\/JCO.2003.04.130","article-title":"Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205)","volume":"21","author":"Ohtsu","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.soc.2018.02.006_bib70","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2004.01.140","volume":"22","author":"Bouch\u00e9","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"31","key":"10.1016\/j.soc.2018.02.006_bib71","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","article-title":"Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group","volume":"24","author":"Van Cutsem","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.soc.2018.02.006_bib72","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1200\/JCO.2007.13.9378","article-title":"Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie","volume":"26","author":"Al-Batran","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.soc.2018.02.006_bib73","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/annonc\/mdn166","article-title":"Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction","volume":"19","author":"Dank","year":"2008","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.soc.2018.02.006_bib74","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","article-title":"S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial","volume":"9","author":"Koizumi","year":"2008","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.soc.2018.02.006_bib75","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/annonc\/mdn717","article-title":"Capecitabine\/cisplatin versus 5-fluorouracil\/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial","volume":"20","author":"Kang","year":"2009","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.soc.2018.02.006_bib76","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2009.25.4706","article-title":"Multicenter phase III comparison of cisplatin\/S-1 with cisplatin\/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial","volume":"28","author":"Ajani","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"31","key":"10.1016\/j.soc.2018.02.006_bib77","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1200\/JCO.2013.54.1011","volume":"32","author":"Guimbaud","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.soc.2018.02.006_bib78","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.ejca.2011.06.002","article-title":"Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer\u2013a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)","volume":"47","author":"Thuss-Patience","year":"2011","journal-title":"Eur J Cancer"},{"issue":"13","key":"10.1016\/j.soc.2018.02.006_bib79","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1200\/JCO.2011.39.4585","article-title":"Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone","volume":"30","author":"Kang","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.soc.2018.02.006_bib80","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1470-2045(13)70549-7","article-title":"Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial","volume":"15","author":"Ford","year":"2014","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.soc.2018.02.006_bib81","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1007\/s10120-015-0542-8","volume":"19","author":"Nishina","year":"2016","journal-title":"Gastric Cancer"},{"issue":"18","key":"10.1016\/j.soc.2018.02.006_bib82","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1200\/JCO.2009.27.7988","article-title":"Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203","volume":"28","author":"Sun","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.soc.2018.02.006_bib83","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s10637-010-9438-y","article-title":"Phase II study of sunitinib as second-line treatment for advanced gastric cancer","volume":"29","author":"Bang","year":"2011","journal-title":"Invest New Drugs"},{"issue":"6","key":"10.1016\/j.soc.2018.02.006_bib84","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s10637-013-0020-2","article-title":"Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study","volume":"31","author":"Martin-Richard","year":"2013","journal-title":"Invest New Drugs"},{"issue":"6","key":"10.1016\/j.soc.2018.02.006_bib85","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1470-2045(13)70096-2","article-title":"Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial","volume":"14","author":"Waddell","year":"2013","journal-title":"Lancet Oncol"},{"issue":"31","key":"10.1016\/j.soc.2018.02.006_bib86","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1200\/JCO.2012.48.3552","article-title":"Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study","volume":"31","author":"Ohtsu","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"9911","key":"10.1016\/j.soc.2018.02.006_bib87","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.soc.2018.02.006_bib88","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2013.53.6136","article-title":"Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN\u2013a randomized, phase III study","volume":"32","author":"Satoh","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.soc.2018.02.006_bib89","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.soc.2018.02.006_bib90","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00280-015-2811-y","article-title":"Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer","volume":"76","author":"Chua","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.soc.2018.02.006_bib91","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.ejca.2014.12.015","article-title":"Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer","volume":"51","author":"Ryu","year":"2015","journal-title":"Eur J Cancer"},{"issue":"13","key":"10.1016\/j.soc.2018.02.006_bib92","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","article-title":"Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction","volume":"34","author":"Li","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.soc.2018.02.006_bib93","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s10120-011-0027-3","volume":"14","author":"Miyashiro","year":"2011","journal-title":"Gastric Cancer"},{"issue":"6","key":"10.1016\/j.soc.2018.02.006_bib94","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/00000421-200212000-00019","article-title":"Adjuvant intraperitoneal chemotherapy with cisplatinum, mitoxantrone, 5-fluorouracil, and calcium folinate in patients with gastric cancer: a phase II study","volume":"25","author":"Topuz","year":"2002","journal-title":"Am J Clin Oncol"},{"issue":"42","key":"10.1016\/j.soc.2018.02.006_bib95","first-page":"1776","article-title":"Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study","volume":"48","author":"Yonemura","year":"2001","journal-title":"Hepatogastroenterology"},{"issue":"1","key":"10.1016\/j.soc.2018.02.006_bib96","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s101200100013","article-title":"A\u00a0controlled clinical study of serosa-invasive gastric carcinoma patients who underwent surgery plus intraperitoneal hyperthermo-chemo-perfusion (IHCP)","volume":"4","author":"Kim","year":"2001","journal-title":"Gastric Cancer"},{"issue":"5","key":"10.1016\/j.soc.2018.02.006_bib97","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1097\/00000658-199011000-00005","article-title":"Positive results of combined therapy of surgery and intraperitoneal hyperthermic perfusion for far-advanced gastric cancer","volume":"212","author":"Fujimoto","year":"1990","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.soc.2018.02.006_bib98","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/BF01675656","article-title":"Hyperthermo-chemotherapy combined with cytoreductive surgery for the treatment of gastric cancer with peritoneal dissemination","volume":"15","author":"Yonemura","year":"1991","journal-title":"World J Surg"},{"issue":"4","key":"10.1016\/j.soc.2018.02.006_bib99","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.gassur.2003.12.014","article-title":"Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer","volume":"8","author":"Hall","year":"2004","journal-title":"J\u00a0Gastrointest Surg"},{"issue":"11","key":"10.1016\/j.soc.2018.02.006_bib100","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.ejso.2007.12.003","article-title":"Advanced gastric cancer with or without peritoneal carcinomatosis treated with hyperthermic intraperitoneal chemotherapy: a single western center experience","volume":"34","author":"Scaringi","year":"2008","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"10.1016\/j.soc.2018.02.006_bib101","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/jso.21519","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat gastric cancer with ascites and\/or peritoneal carcinomatosis: results from a Chinese center","volume":"101","author":"Yang","year":"2010","journal-title":"J\u00a0Surg Oncol"},{"issue":"5","key":"10.1016\/j.soc.2018.02.006_bib102","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1245\/s10434-013-3327-5","article-title":"Aggressive locoregional surgical therapy for gastric peritoneal carcinomatosis","volume":"21","author":"Magge","year":"2014","journal-title":"Ann Surg Oncol"}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320718300164?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320718300164?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:02:38Z","timestamp":1760961758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055320718300164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":102,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S1055320718300164"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2018.02.006","relation":{},"ISSN":["1055-3207"],"issn-type":[{"value":"1055-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolving Treatment Strategies and Outcomes in Advanced Gastric Cancer with Peritoneal Metastasis","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soc.2018.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}